Chinook Therapeutics, Inc.
KDNYNASDAQHealthcare
$40.39
+$0.09(+0.22%)
Market Cap$2.7B
P/E Ratio—
52W High$40.51
52W Low$18.34
Chinook Therapeutics, Inc. (KDNY) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · KDNY · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $6.13M | $51.63M | $0.83M | $17.26M | $15.09M |
| Cost of Revenue | $1.72M | $1.69M | $0.42M | $0.55M | $0.58M |
| Gross Profit | $4.41M | $49.94M | $0.41M | $16.70M | $14.50M |
| Gross Margin %(computed) | 71.90% | 96.73% | 48.97% | 96.79% | 96.13% |
| Operating Expenses | |||||
| R&D Expenses | $141.21M | $96.99M | $36.05M | $17.01M | $75.84M |
| G&A Expenses | $36.29M | $31.90M | $19.07M | $2.96M | $36.03M |
| Total Operating Expenses | $179.22M | $130.57M | $55.54M | $19.97M | $115.86M |
| Operating Income | ($185.08M) | ($99.04M) | ($56.23M) | ($19.97M) | ($101.36M) |
| Operating Margin %(computed) | — | -191.84% | — | -115.69% | -671.84% |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $7.18M | $0.00M | $0.01M | $0.03M | $0.00M |
| Income Before Tax | ($180.27M) | ($99.21M) | ($83.63M) | ($46.52M) | ($96.14M) |
| Income Tax Expense | $4.34M | $2.09M | ($2.00M) | $0.33M | ($0.78M) |
| Net Income | ($184.62M) | ($101.30M) | ($81.62M) | ($46.85M) | ($95.36M) |
| Net Margin %(computed) | — | -196.22% | — | -271.47% | -632.05% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.87 | $-2.22 | $-6.20 | $-1.11 | $-0.00 |
| Wtd Avg Shares | 64.37M | 45.61M | 13.17M | 42.16M | 78812.41M |
| EBITDA | ($164.20M) | ($57.17M) | ($53.98M) | ($19.45M) | ($101.36M) |
| EBITDA Margin %(computed) | — | -110.74% | — | -112.68% | -671.84% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Chinook Therapeutics, Inc. data
About Chinook Therapeutics, Inc. (KDNY) Income Statement
Chinook Therapeutics, Inc. (KDNY) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, KDNY reported revenue of $0.01B, gross profit of $0.00B (gross margin 71.90%), and net income of ($0.18B) — a net profit margin of -3012.65%.
Frequently asked questions
KDNY · 4 questionsChinook Therapeutics, Inc. (KDNY) reported revenue of $0.01B for 2022, down 88.1% year-over-year.
KDNY revenueKDNY salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09